Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

Agilent to Announce Second-Quarter Fiscal Year 2025 Financial Results on May 28Photo, wide shot, wide-angle lens,  Home appliance manufacturer, neutral atmosphere, photo by Joe Cornish: https://img.theapi.app/temp/fb3845ac-e3c6-43ef-86c1-b57ed8c272c4.png
Agilent to Announce Second-Quarter Fiscal Year 2025 Financial Results on May 28


Agilent Technologies Inc. (NYSE: A) will release financial results for the second quarter of fiscal year 2025 after the stock market closes on Wednesday, May 28. In addition, the company will host

ACIP Votes to Expand Recommendation for Pfizer’s RSV Vaccine ABRYSVO® to Include Adults Aged 50 to 59 at Increased Risk of Disease
ACIP Votes to Expand Recommendation for Pfizer’s RSV Vaccine ABRYSVO® to Include Adults Aged 50 to 59 at Increased Risk of Disease


Pfizer Inc. (NYSE: PFE) announced today that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for

New Report from the Humana Foundation Examines Best-Practices in Community-Engaged Research
New Report from the Humana Foundation Examines Best-Practices in Community-Engaged Research


The Humana Foundation, the philanthropic arm of Humana Inc. for the past 44 years, today announced the publication of its new report, Strengthening Science and Community Impact Through Equitable

Acadia Healthcare Announces Date for First Quarter 2025 Earnings Release
Acadia Healthcare Announces Date for First Quarter 2025 Earnings Release


Acadia Healthcare (NASDAQ: ACHC) (“Acadia” or the “Company”) today announced that it will release its first quarter 2025 financial results on Monday, May 12, 2025, after the close of the market

Inogen to Report First Quarter 2025 Financial Results on May 7, 2025
Inogen to Report First Quarter 2025 Financial Results on May 7, 2025


Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report first quarter 2025 financial

Edwards Lifesciences to Host Earnings Conference Call on April 23, 2025:
Edwards Lifesciences to Host Earnings Conference Call on April 23, 2025


Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended March 31, 2025 after the market closes on Wednesday April 23, 2025, and will host a conference call at

Sensorion to Host a Symposium during ISIET’s International Conference on Inner Ear Therapies on April 26, 2025
Sensorion to Host a Symposium during ISIET’s International Conference on Inner Ear Therapies on April 26, 2025


Regulatory News:



Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss

Sartorius Stedim Biotech publishes unaudited first quarter results for 2025
Sartorius Stedim Biotech publishes unaudited first quarter results for 2025
Sartorius Stedim Biotech publishes unaudited first quarter results for 2025
Charles River Laboratories Schedules First-Quarter 2025 Earnings Release and Conference Call
Charles River Laboratories Schedules First-Quarter 2025 Earnings Release and Conference Call


Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2025 financial results on Wednesday, May 7th, before the market opens. A conference call has been scheduled to

Pfizer Provides Update on Oral GLP-1 Receptor Agonist Danuglipron
Pfizer Provides Update on Oral GLP-1 Receptor Agonist Danuglipron


Pfizer Inc. (NYSE: PFE) today announced the decision to discontinue development of danuglipron (PF-06882961), an oral glucagon-like peptide-1 (GLP-1) receptor agonist, which was being investigated

Savara Announces New Employment Inducement Grant
Savara Announces New Employment Inducement Grant


Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to seven new employees.



On April 9

Amneal Donates $1.5 Million to Support Patients During Parkinson’s Awareness Month
Amneal Donates $1.5 Million to Support Patients During Parkinson’s Awareness Month


Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, today announced donations totaling $1.5 million to multiple patient assistance

EQS-News:  Eckert & Ziegler Proposes Dividend of € 0.50 for FY 2024
EQS-News: Eckert & Ziegler Proposes Dividend of € 0.50 for FY 2024
EQS-News: Eckert & Ziegler Proposes Dividend of € 0.50 for FY 2024
Pfizer Invites Shareholders to Attend Virtual 2025 Annual Meeting of Shareholders on April 24
Pfizer Invites Shareholders to Attend Virtual 2025 Annual Meeting of Shareholders on April 24


Pfizer Inc. (NYSE: PFE) announced today that its shareholders and the general public are invited to access its virtual 2025 Annual Meeting of Shareholders at 9:00 a.m. EDT on Thursday, April 24

EQS-News: Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
EQS-News: Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
EQS-News: Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
EQS-Adhoc: FamiCord AG significantly exceeds annual earnings guidance for 2024 on the basis of preliminary figures
EQS-Adhoc: FamiCord AG significantly exceeds annual earnings guidance for 2024 on the basis of preliminary figures
EQS-Adhoc: FamiCord AG significantly exceeds annual earnings guidance for 2024 on the basis of preliminary figures
Premier, Inc. to Report Fiscal 2025 Third-Quarter Results and Host Conference Call on May 6, 2025
Premier, Inc. to Report Fiscal 2025 Third-Quarter Results and Host Conference Call on May 6, 2025


Premier, Inc. (NASDAQ: PINC) today announced that it will release financial results for its fiscal 2025 third quarter on Tuesday, May 6, 2025, at approximately 6:30 a.m. ET. The company will also

Siegfried shareholders approve all proposals at Annual General Meeting 2025
Siegfried shareholders approve all proposals at Annual General Meeting 2025
Siegfried shareholders approve all proposals at Annual General Meeting 2025
EQS-News: Eckert & Ziegler: US Consul Visits Radiopharmaceutical Production in Braunschweig
EQS-News: Eckert & Ziegler: US Consul Visits Radiopharmaceutical Production in Braunschweig
EQS-News: Eckert & Ziegler: US Consul Visits Radiopharmaceutical Production in Braunschweig
Natus Sensory verstärkt Führungsteam mit Ernennungen in Schlüsselpositionen
Natus Sensory verstärkt Führungsteam mit Ernennungen in Schlüsselpositionen


Natus Sensory freut sich, die Erweiterung seines globalen Führungsteams um drei erfahrene Führungskräfte bekannt zu geben. Damit bekräftigt das Unternehmen sein Engagement für die Förderung von

Natus Sensory Strengthens Executive Team with Key Leadership Appointments
Natus Sensory Strengthens Executive Team with Key Leadership Appointments


Natus Sensory is pleased to announce the addition of three accomplished executives to its global leadership team, reinforcing the company’s commitment to advancing innovation, customer impact, and

EQS-News: Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
EQS-News: Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
EQS-News: Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
Form 8.3 - The Vanguard Group, Inc.: PureTech Health plc
Form 8.3 - The Vanguard Group, Inc.: PureTech Health plc
Form 8.3 - The Vanguard Group, Inc.: PureTech Health plc
GenSight Biologics Announces the Filing of its 2024 Universal Registration Document
GenSight Biologics Announces the Filing of its 2024 Universal Registration Document


Regulatory News:



GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris


Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Viatris, Inc. (“Viatris” or the “Company”) (NASDAQ: VTRS) and reminds investors of the June